Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Heritage Investors Management Corp

Heritage Investors Management Corp boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 4.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,936 shares of the medical equipment provider's stock after acquiring an additional 6,349 shares during the period. Heritage Investors Management Corp owned about 0.08% of Zimmer Biomet worth $16,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Crewe Advisors LLC acquired a new stake in Zimmer Biomet in the 1st quarter valued at $31,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet during the third quarter worth about $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet in the second quarter valued at approximately $33,000. J.Safra Asset Management Corp boosted its holdings in shares of Zimmer Biomet by 712.1% in the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 235 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Zimmer Biomet during the second quarter worth $43,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 0.5 %

Shares of ZBH stock traded up $0.51 during trading hours on Tuesday, reaching $108.92. The company's stock had a trading volume of 1,373,886 shares, compared to its average volume of 1,490,657. The firm's fifty day simple moving average is $106.72 and its 200 day simple moving average is $110.58. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90. The stock has a market capitalization of $21.68 billion, a P/E ratio of 20.71, a P/E/G ratio of 1.97 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period last year, the company earned $1.65 earnings per share. The company's revenue was up 4.1% on a year-over-year basis. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet's payout ratio is 18.25%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Wolfe Research initiated coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They issued a "peer perform" rating on the stock. BTIG Research dropped their price objective on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a report on Thursday, October 3rd. Robert W. Baird lowered their price objective on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. Finally, TD Cowen lowered their target price on Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating on the stock in a report on Friday, September 6th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.